Remdesivir was shown to inhibit RNA-dependent RNA-polymerases (RdRp) from distinct viral families such as from Filoviridae (Ebola) and Coronaviridae (SARS-CoV, SARS-CoV-2, MERS). In this study, we tested the ability of remdesivir to inhibit RdRps from the Flaviviridae family. Instead of remdesivir, we used the active species that is produced in cells from remdesivir, the appropriate triphosphate, which could be directly tested in vitro using recombinant flaviviral polymerases. Our results show that remdesivir can efficiently inhibit RdRps from viruses causing severe illnesses such as Yellow fever, West Nile fever, Japanese and Tick-borne encephalitis, Zika and Dengue. Taken together, this study demonstrates that remdesivir or its derivatives have the potential to become a broad-spectrum antiviral agent effective against many RNA viruses.
- MeSH
- adenosintrifosfát analogy a deriváty chemie farmakologie MeSH
- antivirové látky chemie farmakologie MeSH
- Betacoronavirus účinky léků enzymologie MeSH
- COVID-19 MeSH
- Flavivirus účinky léků enzymologie MeSH
- inhibiční koncentrace 50 MeSH
- koronavirové infekce farmakoterapie virologie MeSH
- lidé MeSH
- pandemie MeSH
- RNA-dependentní RNA-polymerasa antagonisté a inhibitory metabolismus MeSH
- RNA-viry účinky léků enzymologie MeSH
- SARS-CoV-2 MeSH
- virová pneumonie farmakoterapie virologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
